



QIAGEN GmbH  
QIAGEN Str. 1  
40724 Hilden, Germany

September 2023

## QIAGEN® Clinical Insight Interpret Release Notes

Dear valued customer,

At QIAGEN, we are continuously making improvements to provide the highest level of performance with our software. Consequently, we are pleased to inform you about the latest release of QCI® Interpret.

### Release Highlights

**QCI leverages artificial intelligence (AI) to expand the bibliography:** To provide broader coverage of the clinical exome, AI-derived literature references have been integrated into the Bibliography section. The new **Source** icons, "Context" disease details, and "Show Phenotype-Related References Only" filter provide full control over the use of these automatically extracted references.

**Gene transcripts with MANE select status are now the default:** QCII embraces this community effort to standardize clinical transcripts for reporting. "MANE Select" and "MANE Plus Clinical" labels appear in the variant viewer dropdown, in the "Effect on Protein" section of the Variant Details page.

**Enhanced phenotype-driven ranking:** Variant-specific qualities are now taken into account beyond the similarity of the gene–disease phenotypic spectrum to patient symptoms by providing an improved PDR score ranking of candidate variants for rapid clinical exome review.

**More precise structural variant filtering:** The Confidence filter now supports thresholds for copy number gains, losses, fusions, and rearrangements. A "gene-associated structural variants" filter enables retention of structural variants that are partly in non-coding gene regions.

**Improved ACMG PVS1 criteria with the modified strength workflow and informative notices:** ClinGen's PVS1-modified strength recommendations are now applied to improve the ACMG classification of loss of function variants. PVS1 notices indicate the specific decision tree branch applied.

**Enhanced accuracy of the Somatic reporting policy:** The 1 year expiration was removed for user set assessments in Somatic reporting policies v1 and v2. User assessments are now automatically re-reported indefinitely in new cases for all reportability types, including artifacts.

Software version: 9.2.0.20230922



**New workflows for streamlined report revisioning and labeling:** A new **Label Report** button on the Review and Report page enables the addition (or removal) of a report label including Addendum, Amendment, Correction, or custom text. The new **Addend Report** button on signed out tests creates a copy, that is labeled with Addendum, to facilitate issuing an updated report. API enhancements enable a new report to replace an existing one (correction) or creation of an amended/addended report copied from an existing report with updated information (such as patient or physician information) provided via the API. The report label can be displayed on customized reports. A fee may apply to update existing customized report templates.

**Refined handling for multiple fusions with the same first breakpoint:** On the Review & Report page, multiple fusions with the same first breakpoint location and gene pair were previously collapsed and shown as a single variant. Now the specific fusion breakpoint pair(s) are maintained on the Review & Report page for additional clarity.

**Advanced handling of EGFRvIII:** EGFR exon 2–7 deletion and EGFR e1:e8 rearrangements are now handled the same for identifying treatments and clinical trials. Non-specific EGFR targeted treatments and trials are no longer automatically reported for EGFRvIII.

**Increase privacy and protection:** For security and data privacy, idle sessions now result in automatic logout after 30 minutes of inactivity. A notice appears minutes before a session will be ended which permits the session to be extended.

## Release Information

### Product(s):

QIAGEN Clinical Insight (QCI) Interpret,  
QIAGEN Clinical Insight (QCI) Interpret One,  
myQCI

**Release Date:** September 22, 2023

**QCI Interpret Version:** 9.2.0.20230922

**MyQCI version:** 1.4.0

**Content Versions:** Please see appendix

## Contact Our Technical Support

Email: [ts-bioinformatics@qiagen.com](mailto:ts-bioinformatics@qiagen.com)

Denmark: +45 80 82 0167, United States: +1-866-464-3684

Hours Americas: 00:00 – 16:00 PST, EMEA: 09:00 – 00:00 CET

Additional Information: Visit us online at <https://digitalinsights.qiagen.com/>

## Intended Use Statement

QCI Interpret (QCII) is a software platform that uses scientific evidence associated with genetic variants related to somatic and hereditary diseases through the in vitro examination of genomic data. QCI Interpret is intended to be used by lab directors, oncology experts, and human genetics experts to help guide patient management decisions.

Software version: 9.2.0.20230922



## Introduction to QCI Interpret

QCI Interpret is a web-based software application for the annotation, classification, and reporting of actionable alterations from next-generation sequencing (NGS) data in clinical genomics laboratories. Published evidence curated by experts into QIAGEN Knowledge Base is used by QCII to provide a powerful tool for increasing the efficiency and accuracy of genomic alteration, interpretation, and reporting. QCII uses a rules-based approach to automatically compute pathogenicity classifications (Pathogenic to Benign) and actionability classifications (Tiers 1 to 4) for each alteration according to professional guidelines from ACMG/AMP and AMP/ASCO/CAP, respectively. Pathogenicity and actionability classifications in QCII are accompanied by transparent references to the criteria and evidence supporting the classifications. This workflow starts with a variant call format (VCF) file, so it is compatible with the output from any NGS platform. The final report includes the alterations, interpretations, and references specified through the assessment process, which has customizable automation capabilities allowing for streamlined clinical decision support workflows.

## Introduction to myQCI

MyQCI is an easy-to-use administrative application for QCI that enables managing, configuring, and customizing key components of your test menu including test configuration, PDF report templates, and electronic signatures.

## Introduction to QDIAT


The QIAGEN Digital Insights Administrative Tool (QDIAT) empowers lab administrators to independently onboard new team members, configure groups of users, and generally manage permissions within the account associated with one or more licenses. This tool also enables review of usage of the software.

Software version: 9.2.0.20230922

## What's New in QCI Interpret

### Expanded Bibliography with the Assistance of AI

AI-derived article references are now integrated into the Bibliography. This AI content broadens article coverage for variants in genes beyond the routinely tested certified genes that QIAGEN monitors and manually curates new publications on daily, to the clinical exome. Because this new AI content is not manually reviewed, it is categorized into medium and high accuracy based on estimated false positive rate. We added a new column with “Source” icons (1) with the option to sort (2) and disease “Context” details (when present) to all references (3). The new **Show Phenotype-Related References Only** filter option narrows down the results to focus exclusively on phenotype-related references (4).



### Enhanced Phenotype-Driven Ranking of Variant List Page

Phenotype-Driven Ranking (PDR) filter score now considers attributes of the patient's variant in each gene, such as pathogenicity, mode of inheritance (MOI), and CADD score.

## QCI Now Aligns to MANE Transcripts

The gene transcripts recommended for clinical reporting based on Matched Annotation from NCBI and EMBL-EBI (MANE) Select designations, are now the default transcripts. “MANE Select” and “MANE Plus Clinical” labels appear in the variant viewer transcript dropdown under the "Effect on Protein" section of the Variant Details page as well as the transcripts menu in the Variant Directory.

**Known issue:** A total of 30 genes have additional transcripts that are inferred to be MANE Select due to being orthologs. In rare cases, the inferred transcript is the default.

### *Notice for Users of NCBI36 (hg18)*

The NCBI36 (hg18) reference genome and associated data will no longer be supported in the next release. Please plan to export any such results needed before the end of 2023. Currently, hg18 is only available in the United States.

## Improved Structural Variant Filtering

To provide more selective filtering control of structural variants that span both coding and non-coding regions, the “Exonic hard filter” option in the analysis creation workflow has been expanded to include such “gene-associated structural variants”.

Both the Confidence filter and Predicted Deleterious filters settings are updated and more expressive. The previous version of these filters follows the same logic as before. The filters can be edited and applied in existing analyses, or a new filter cascade can be created with the new versions and saved for use with existing test product profiles to use their new capabilities.

To use the updated Confidence and Predicted Deleterious filters in existing Test Product Profiles, a user with Lab Director privileges will need to make a copy of the existing filter cascade, update the filter(s) in the cascade, and then save the updated filter cascade. Then, this updated filter cascade should be linked to the right Test Product Profile(s) by editing the TPP in myQCI.

### *Confidence Filter Structural Variant Thresholds*

The Confidence filter now has copy number (CN)/fold change (FC) thresholds for CN gains and CN losses, and breakpoint spanning read thresholds for fusions/rearrangements. Both are now separate from the read depth filter threshold applied to small variants.

### *Predicted Deleterious Filter Improvements*

The **Predicted Deleterious** filter now enables structural variants that only overlap non-coding gene regions, which are not expected to impact transcription, to be exclude with the new 'gene associated structural variants' option.

The computed ACMG classification filtering criteria is based on the computed classifications for the respective hereditary and somatic workflows. Previously, QCII would filter out the EGFRvIII rearrangement in the somatic workflow because it was classified as a VUS in the hereditary context; now, EGFRvIII is retained in the somatic workflow since it is classified as pathogenic in the somatic context.

Software version: 9.2.0.20230922



Previously, the **Predicted Deleterious** filter required CN values in the VCF to recognize structural variants for the “Copy Number Gain” and “Copy Number Loss” criteria. The filter has been improved to also recognize SVTYPE=DUP and INS as Amplification and SVTYPE=DEL as Deletion.

Previously, the Predicted Deleterious filter used only SVTYPE=Fusion to recognize structural variants for the “Gene Fusion” criteria. The filter has been improved to also recognize SVTYPE=INV and BND and has been renamed 'Gene Fusions/Rearrangements'.

## Variant Details Page Improvements

### *Laboratory Observations Section*

The header of the Laboratory Observations section now reflects the total number of tests/analyses seen by the lab.

The default view of the Laboratory Observations section now filters for prior user set assessments, which speeds up loading time. To display all prior assessments including those performed by [system@qiagen.com](mailto:system@qiagen.com), the option can be unchecked.

Previously in the Laboratory Observations section, whenever a genotype was not provided in the original VCF, the genotype for the variant would always appear as “HET” by default. This has been changed, so that the system does not infer a “HET” genotype for somatic cases.

### *Effect on Protein Section*

The variant viewer in the “Effect on Protein” section of the Variant Details page now renders much faster.

The variant viewer now shows adjusted nonsense-mediated decay (NMD) positions (from the QIAGEN Knowledge Base) that differ from the standard location of "the last 50 bases of the penultimate exon".

## Improved Operability

### *Idle Session Logout*

For data privacy and security compliance, after a long period of inactivity an automatic logout now occurs. This reduces the risk of a user leaving sensitive information visible in their browser while away from their computer. A warning notification is shown to continue the session with a click prior to the automatic logout at timeout.

## ACMG/ClinGen-Related Improvements

QCII computed gene-disease validity provided for all gene-disease was updated to align with ClinGen’s Clinical Validity SOP v9.

### *PVS1*

The computed ACMG classification now automatically applies the modified strength PVS1 workflow based on the ClinGen SVI PVS1 recommendations. PVS1 Notices indicate which decision branches were applied for clarity. The export XML will show the modified PVS1 strength, but it currently does not contain a notifications area to communicate the PVS1 Notices.

Software version: 9.2.0.20230922

A new PVS1 Notice also indicates rare single nucleotide splice site substitutions that trigger PVS1 when the reference sequence, at the position of the variant of interest, does not match the consensus sequence GT or AG. Careful manual review of splice predictions is recommended. This new PVS1 Notice does not impact how PVS1 is triggered. QCI does not actively check if the reference sequence is the canonical/consensus GT-AG to determine if PVS1 workflow is applicable or not.

A new PVS1 Notice notes deletions in repeat regions in canonical splice variants that triggered PVS1. Careful review of these scenarios is recommended to confirm that PVS1 is applicable.

### *PA2*

The QIAGEN PA2 criteria (founder mutations) now only matches specific genomic variants rather than less specific protein changes. No changes were made as to how PA2 is applied in terms of phenotype specificity.

### *BS1*

The ACMG BS1 criteria now uses ClinGen's BS1 maximum expected pathogenic allele frequencies for 54 genes. These thresholds are lower than the default QCII-computed BS1 thresholds, which are derived from disease prevalence, which reduce variants of uncertain significance in favor of likely benign.

## Clinical Workflow Improvements

### *Fusion Display on Review & Report Page Improvement*

In the rare situations where multiple fusions are detected for the same gene pair, the Review & Report page now shows the specific pair marked reportable in the variant list view. Previously, the Review & Report page would show a representative fusion with the same first breakpoint in such cases, the first in the list. This might not represent the most biologically relevant or clinically significant fusion (depending on the second breakpoints across the fusions with the same gene pair) or the fusion with the highest read count. The specific fusion selected on the variant list page is now passed all the way to the report.

**Note:** Tests created prior to this improvement will continue to follow the previous representative fusion logic.

### *Italicization of gene symbols in interpretative comments*

HGNC gene symbols in report headers and in QCII provided gene interpretive comments have been italicized. QCII does not currently detect gene names inside user-provided report comments and will not automatically render those gene names in italics.

### *Removed 1 year expiration from Somatic reporting policies v1 and v2*

The 1 year expiration on re-reporting user set assessments has been removed from the Somatic reporting policies v1 and v2. Effective immediately, the most recent user set assessment for each variant will continue to be automatically re-reported indefinitely in new cases with the variant for all reportability types, including artifact. This enhancement ensures the current computed classification is not used by the Somatic reporting policy when a user assessment exists.

### *Other usability improvements*

In the Review & Report page, the **Sign Out** and **Preview Report** button positions have been swapped for improved usability.

Software version: 9.2.0.20230922

## New Report Revision Tools

### *Updates via API*

The **/v1/datapackages** API endpoint permits metadata update (e.g., patient, physician, specimen information) of an existing test to create a new revised report (either with the same accession or a newly provided one). Revised reports with only metadata or comment updates do not count toward test usage. Each revised report in QCII retains a link to the source test (shown at the top of the Review & Report page).

For reference, common terminology for types of reports are as follows:

**Final:** Initial state of a test before it is amended, addended, or corrected. This is the initial sign-out of a case.

**Amendment:** Updates to the test metadata with new information that should appear on the final report. This is typically a change required solely due to typographical errors. The source test including comments is cloned and the specified metadata changes are made to the new copy.

**Addendum:** Updates to a test to report additional results typically via the overall test comment. Like an amendment, any updates to metadata are also applied.


**Correction:** Replaces a test with new sample data, typically due to laboratory error.

### *Updates to Test Status via User Interface*

From within the UI, the ability to addend a report (e.g., clone an existing test) is available. After a case is signed out, an **Addend Report** button allows users to create a copy of the current test. The copied test will display an 'Addendum' label, visible within the test itself, on the Test List page, and on the PDF report.

**Note:** If the desired label does not appear in the report header after clicking the **Preview Report** button, then it means your report template will need to be modified. Please contact customer support at [ts-bioinformatics@qiagen.com](mailto:ts-bioinformatics@qiagen.com) for more information on enabling report labels on your report, a fee may apply to update existing customized report templates.





**1** Addend Report

**2** Create an Addendum

To create a copy of this test prior to issuing as a new Addendum to update comments or results, first specify whether you want a new accession name (such as by adding a -1 suffix):

variant\_data\_1\_variant


Optional test note (viewable by your organization and does not appear on the report)

Optional test note here. .

After clicking Submit, you will be redirected to the Test List page while the Addendum is processed. (maximum 4000 characters)

Cancel Submit

In the Review & Report page, a new **Label Report** button empowers users to add, change, or remove report labels, such as Amendment, Addendum, Correction, or custom text (e.g., equivalent non-English terms or “Preliminary”). A revised report created from a previous test, created both through the UI and API, includes a convenient link that goes back to the original test. This streamlined navigation allows for easy reference and review of the original overall test comment and contents.



**1** Label Report

**2** Label Report

A report label can be used to indicate the report is a revision. You may add, change, or remove the report label associated with this test.

**Note:** Clinical report templates created prior to the implementation of this feature may not contain the necessary report elements to display the selected label. If the desired label does not appear in the report header after clicking the “Preview Report” button, then it means your report template will need to be modified. Please contact customer support at [ts-bioinformatics@QIAGEN.com](mailto:ts-bioinformatics@QIAGEN.com) to initiate this process.

Amendment (update of patient, physician, or specimen metadata for report)

Addendum (update reported results or overall comment)

Correction (updated data (and metadata) for report)

Custom:

No report revision label

Cancel Submit

Software version: 9.2.0.20230922



All newly generated report revisions, whether created through the UI or API, are added to the Variant Directory. To distinguish these report revisions from the original tests, a new column called "Revision Type" displays the initial revised report type, such as Amended, Added, or Corrected.

If a test is shared with a user group, all members of the group see the test label (e.g. amended, added, or corrected).

## Somatic Workflow Specific Updates

The treatments and clinical trials for EGFR exon 2–7 deletion and EGFR e1:e8 rearrangement are now both aligned with EGFRvIII.

The treatments and trials matching for EGFRvIII have been revised so that EGFR targeted treatments and trials are no longer automatically reported.

For combination genotype findings, the drugs/trials matching will ignore the protein expression positive biomarker as a requirement for matching. Previously, QCI would only match Alpelisib (approved for use in ER+ breast carcinoma with PIK3CA mutations) when there was an ESR1 variant in the same case. This improvement no longer requires an ESR1 variant to be in the same case and allows Alpelisib to be matched despite QCI not considering expression marker(s).

In myQCI, when editing or creating a new Test Product Profile, users can now specify the trial matching radius in increments of 100 miles up to 500 miles.

## QCII-One and Expert Interpretation Updates

When cases are sent for Expert Interpretation, the Primary Tumor Site is now also automatically provided to the interpretation team. This information may be used to improve the specificity of the content and is used only for Curation Service cases.

Interpretative comments for nonsense (stop) variants do not get included with frameshift variants and vice versa.

Previously, MSI-stable and MSI-low conditions would both return MSI-low comments. Now a Microsatellite Instability stable specific comment is returned by Expert Interpretation.

## Minor Improvements

- The “User Guide” link in the top-right navigation bar of QCII and myQCI were updated to “Documentation” to link to a new webpage with the current user guide and release notes.
- Previously, in the Variant List page, the yellow Conflicting Criteria flag would be removed from the variant tile when a user set assessment or auto-assessment by system@qiagen.com was performed. This could be confusing, so now the yellow Conflicting Criteria flag is only removed from the variant tile when the variant has been assessed, because the user presumably reviewed and resolved any conflicts.
- The legacy customer support email [support-ingenuity@qiagen.com](mailto:support-ingenuity@qiagen.com) has been removed from the app and is replaced with [ts-bioinformatics@qiagen.com](mailto:ts-bioinformatics@qiagen.com).
- When user clicks **Contact Us** from the Test List or Sample List page, the pop-up window now directs them to use the **Contact Us** button in the specific test or variant page if that is what they want to discuss.
- ActivationCode and PromotionCode XML elements were not used so are deprecated and no longer part of the current XML schema (1.19).

## Known Issues

- With QCI’s recent support for the HG38 gene model, QIAGEN noticed an inconsistency in the number of genes that are available on the HG38 reference transcript. There is currently a gap on the new gene model that affects the following genes associated with either treatment or relevant gain/loss of function data: ATP10A, CD74, FFAR1, GSTT1, LAGE3, LOC102724788, MST1, NTF4, POU2F2, SNAPC4, and SULT1A1.
- With the implementation of MANE transcripts, 30 genes have additional transcripts that are inferred to be MANE Select due to them being orthologs. In rare cases, the inferred transcript could be selected as the default; however, this has minimal impact on the associated computed classifications.
- In the Common Variants filter, the “established Pathogenic common variant” does not appear as a blue hyperlink, although it is still clickable and functional.
- The PA2 criterion is supposed to only apply to the hereditary workflow; however, it is also being triggered in the somatic workflow.
- For the newly added PVS1 Notice of single nucleotide splice site substitutions that trigger PVS1, when the reference sequence does not match the consensus sequence GT or AG, QCI is specifically checking the reference nucleotide at the same position of the variant of interest (i.e., QCI checks for either G or T, or either A or G) and is not checking both reference nucleotides (i.e., G and T, or A and G).

Software version: 9.2.0.20230922

- For the newly added “Context” disease displayed as part of the Artificial Intelligence implementation, for a small set of articles some disease terms include extraneous curly brackets.
- The Bibliography for copy number variants is sorted by source rather than similarity score.
- For multi-sample analysis, when a sample does not pass filter criteria then the iconography in the Variant List table appears in solid black instead of light gray to indicate that the sample did not pass the filter criteria.
- In this release, we have enabled the ability to report EGFR-targeted treatments and trials for EGFRvIII. However, an unintended consequence has been the additional display of other gene-targeted treatments and trials for other gene-deletion/loss variants. It is important to note that these gene-targeted treatments and trials are not automatically reported.
- The somatic reporting policy does not automatically report cetuximab resistance for NRAS mutations in colorectal cancers with the content update in the release. However, cetuximab can still be manually reported as usual. Panitumumab remains automatically reported as Tier 1A resistant for NRAS mutations in colorectal cancers. The root cause in the content update has been identified and will be resolved within weeks in the next rapid content update.
- We have identified an issue that results in the loss of the 2D-R treatment association of dabrafenib to KRAS Q61H. This issue is specific to Erdheim–Chester disease. However, as 2D-R findings are triggered in a disease-agnostic manner within QCII, this could impact KRAS Q61H in any indication. It is important to note that other resistance findings associated with KRAS Q61H remain unaffected. The issue will be resolved within weeks in the next rapid content update.
- Allele Fraction rounding discrepancy in the test (Variant List table, Variant Summary section, Variant Details) versus in the report (i.e., Review & Report page, report PDF, export XML). In the test, the Allele Fraction values are rounded up (e.g., 0.34669% displays as 0.35%) whereas on the report the value is truncated (e.g., 0.34669% displays as 0.34%).
- The Publications column in the Variant List page (hereditary workflow only) is meant to reflect the number of unique PMIDs that the user can find in the Bibliography section for the variant of interest; however, a small number of cases will have a number that is slightly reduced because PMIDs that were sourced through AI or from treatment and trial-related references are currently not included in the total count.
- For reports, if the report template uses the same default font as the demo report, then the alpha symbol (e.g., PKC- $\alpha$ ) appears as a hashtag (e.g., PKC##).
- Fusions are displayed twice in the Variant Directory. For example, the FGFR3-TACC3 fusion is listed in the Variant Directory as “FGFR3-TACC3 fusion” along with another entry for the “TACC3-FGFR3 rearrangement”.
- In myQCI, when working in the Visual Template Editor, the user cannot change the font size for report title and section title. The workaround is to go into **Advance Editor** and manually change the style.css if needed.

## Bug Fixes

In order of appearance in the UI:

Issue number	Description
ICL-19537	myQCI Test Product Profiles – Sometimes when a TPP was cloned, the workflow pipeline would mistakenly change from Hereditary to Somatic. This unintended change of the workflow has been addressed.
ICL-19297	In Step 3 of the analysis creation workflow (somatic workflow only), the URL to ISCN nomenclature was corrected.
ICL-20449	Supplementary PDF/JPG/JPEG files added to a test could only be viewed when a test was shared with a specific user and not a user group. This has been corrected so that these files can be shared with user groups.
ICL-20333	Some structural variants affecting a single gene were displaying the cytoband information as part of the variant display (e.g., “FGFR1-p11.22”). This has been corrected, so that the cytoband is no longer included in the variant display (e.g., “FGFR1 amplification” or “FGFR1 exon 2-18 amplification”).
ICL-19782	Bibliography section – references with special characters are now correctly displayed (e.g., Lavallée VP et al).
ICL-20355	Variant List page -- Previously, in Triage Mode if you began a new assessment for a variant, then clicked on another variant without saving the first one, a pop-up notice would ask if you wanted to save the changes. If you elected to save the changes, then changes to both the first and second variant would save. This has been corrected so that when you choose to save via the pop-up notice, only changes to the first variant are saved.
ICL-20124	Variant List page – Previously, in Triage Mode as the user progressed down the list of variants, a variant tile would turn white, and the page would need to be refreshed to correct itself. This has been fixed so that the variant tiles continue to display the color that corresponds to the computed classification or assessment.
ICL-18446	Variant List page (somatic workflow only) – In analyses with multiple samples for either cases or controls, QCI would show a “-“ under the “Case – Quantity” and “Control – Quantity” columns for all samples and then the user had to hover over each “-“ to view any present values. Now, instead of a “-“, the values (i.e., copies, fold change, or reads) are displayed for cases with multiple samples.
ICL-20508	Variant List page (somatic workflow only) – Variants in genes with refuted evidence are now visible in the table when they were previously hidden.
ICL-20167	Variant List page and Review & Report page – Previously, if a user marked a variant as “Not Reportable” from the Review & Report page and then went back to the Variant List page and unchecked the “Not Reportable” option under the View Settings, some of the “Not Reportable” variants would still appear in the Variant List table. This has been addressed so that upon returning to the Variant List page, the table correctly removes all “Not Reportable” variants from display when the “Not Reportable” option is unchecked.
ICL-20905	Variant Details – Under the Assessment section, users are now consistently given a notice when their assessment note exceeds the character limit. The <b>OK</b> button is also disabled to prevent submission of any lengthy note that could get truncated by the system.
ICL-20156	Variant Details (somatic workflow only) – Under the Clinical Trials section, when using “Change Patient Location” the page needed to be manually refreshed to re-calculate the clinical trials. This has been fixed.
ICL-21175	Variant Details – Under the Reported Functional Impact section, the Predicted Biochemical Impact results from MaxEntScan displayed “No Prediction” when there was no prediction as well as when the prediction was “Normal”. This has been corrected so that “Normal” is displayed when appropriate.
ICL-20021	Variant Details page -- The URL to CentoMD, which is no longer in operation, was removed from under the Clinical Cases from Other Laboratories section.
ICL-20152	Review & Report page – Variants are displayed in groups based on phenotype. Now, the phenotype groups are listed alphabetically.
ICL-20095	Review & Report page – The display for rearrangements in the Review & Report page was incorrect when one of the fusion partners was without a gene name. For example, Chr5:q33.1-ROS1 would appear as Chr6:q22.1-ROS1 in the Review & Report page with the 5' partner swapped with the chromosome and cytoband details of the 3' partner. This has been addressed so that the fusion/rearrangement is correctly displayed across the application.
ICL-20245	In myQCI visual editor, an issue with the Methods & Limitations textbox and an extra text display has been resolved.

Software version: 9.2.0.20230922

## Content Sources and Versions

QIAGEN Clinical Insight Interpret 9.2.0.20230922

Source	Version
1000 Genome Frequency	phase3v5b
Allele Frequency Community	2019-09-25
BSIFT	2016-02-23
CADD	v1.6
CentomD	5.3
Clinical Trials	K-release
Clinvar	2023-05-08
COSMIC	v97
dbSNP	NCBI36 (hg18) 151, GRCh37 (hg19) 155, GRCh38 155
dbVar	2021_04
DGV	2016-05-15
EVS	ESP6500SI-V2
ExAC	0.3.1
GENCODE	Release 41
gnomAD	GRCh37 (hg19) 2.1.1, GRCh38 (hg38) 3.1.2
HGMD	2023.1
Ingenuity Knowledge Base	K-release
Ingenuity Knowledge Base Snapshot Timestamp	2023-06-03 16:23:26.969
iva	Jun 15 11:47 iva-1.0.266.jar
JASPAR	2013-11
Matched Annotation from NCBI and EMBL-EBI (MANE)	0.95
MITOMAP: A Human Mitochondrial Genome Database. <a href="http://www.mitomap.org">www.mitomap.org</a> , 2019	2020-06-19
NCBI Gene	2022-02-22
OMIM	January 16, 2023
OncoTree	oncotree_2021_11_02
phyloP	NCBI36 (hg18) 2009-11, GRCh37 (hg19) 2014-02, GRCh38 2015-05
PolyPhen-2	v2.2.2 (HumVar)
Refseq Gene Model	2022-08-30
SIFT4G	2016-02-23
TargetScan	7.2
TCGA	2013-09-05
Vista Enhancer	2012-07

If you have further questions, please contact your local QIAGEN representative or contact our Technical Support Center at [www.qiagen.com/support/technical-support](http://www.qiagen.com/support/technical-support).

Best regards,  
QIAGEN

Trademarks: QIAGEN®, Sample to Insight®, QCI® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law. PROM-22381-002 09/2023 © 2023 QIAGEN, all rights reserved.

Software version: 9.2.0.20230922